Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!
04/24/18 Needed context absent from release on “less toxic way to treat brain tumors”
This brings up a very important point. Every day we see an article claiming a breakthrough. Us old pros know it is just hyperbole - not really meant to be taken literally. They are just trying to get their treatment noticed and if they told the truth in the headline, nobody would look at it. But for the new people here, who are desperately looking for anything to help their loved one with a brain tumor, it is very dangerous.
The website noted below digs into these stories and exposes the truth. I like to think that is what we do here also with these editorials about the articles. It gives perspective. Same with our online support groups: https://virtualtrials.com/lists.cfm If you find something online that looks interesting for brain tumor patients, share it with one of the online groups.
04/17/18 Can all the money in the world beat cancer?
Maybe it could! This person identified the collaboration between the Musella Foundation and Cancer Commons as one of the things he would fund if he raises all of that money!
04/14/18 Musella Foundation Co-pay Assistance Program is about to close to new patients
Our copay assist program needs donations. I know most people like to donate to research only, and that is also badly needed. When you donate to the Musella Foundation (a https://virtualtrials.com/donate8.cfm ), we let you specify WHERE your donation will go, with 3 choices:
1. Brain tumor research only - 100% of your donation will go to research. (we also have some specific funds you can donate to such as DIPG or Oligodendroglioma - on our website, click on donations, the Special Funds)
2. Copay assist program - 91% of your donation with go to a needy patient. 9% has to be used to cover the expense of running the program.
3. Anywhere it is needed. This covers the foundations' expenses which allows us to provide our services, as well as educational resources. Anything left over is used for research. Never for copay.
04/12/18 Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.
This is a very important article. Although a small sample, it opens the door to using a BRAF inhibitor for brain tumors that have the BRAF V-600 mutation. Note that this shouldn't be used in other mutations of BRAF, only the V-600 mutation. They found that using these drugs may actually speed up the tumor if they do not have the V-600 mutation.
04/06/18 Phase II clinical trial starts evaluating new drug for glioblastoma
GDC-0084 (RG7666) which is a novel BBB-penetrating PI3K/mTOR inhibitor displaying a high brain-to-plasma ratio (1.9–3.3). It remarkably impedes the proliferation of five GBM cell lines and suppresses the growth of U-87 MG GBM xenografts through decreasing Akt phosphorylation
04/04/18 A One-Two Combo Punch for Lung Cancer
This sounds pretty good. It also worked in a mouse model of glioblastoma, so they are going to start a trial of this combination for Glioblastoma patients. Both parts of the combo are approved so they can be used off label now.
03/30/18 Optune Open House, Newton MA
This is a nice series of meetings for patients and caregivers who use (or are thinking of using) Optune.